MA26353A1 - Procede pour la preparation de 3-{2-[4-(6-fluorobenzo[d] isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-[1,2-a]pyrimidin-4-one - Google Patents

Procede pour la preparation de 3-{2-[4-(6-fluorobenzo[d] isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-[1,2-a]pyrimidin-4-one

Info

Publication number
MA26353A1
MA26353A1 MA27800A MA27800A MA26353A1 MA 26353 A1 MA26353 A1 MA 26353A1 MA 27800 A MA27800 A MA 27800A MA 27800 A MA27800 A MA 27800A MA 26353 A1 MA26353 A1 MA 26353A1
Authority
MA
Morocco
Prior art keywords
fluorobenzo
isoxazol
pyrido
pyrimidin
piperidin
Prior art date
Application number
MA27800A
Other languages
English (en)
Inventor
Rafael Foguet
Jorge Ramentol
Diego Fernandez-Cano
Miguel P Armengol
Francesc X Camps
Juan Sallares
Ines Petschen
Mireia Pasto
Esther Gordo
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MA26353A1 publication Critical patent/MA26353A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA27800A 2002-03-05 2004-07-27 Procede pour la preparation de 3-{2-[4-(6-fluorobenzo[d] isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-[1,2-a]pyrimidin-4-one MA26353A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200531A ES2197801B1 (es) 2002-03-05 2002-03-05 Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.

Publications (1)

Publication Number Publication Date
MA26353A1 true MA26353A1 (fr) 2004-10-01

Family

ID=27772022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27800A MA26353A1 (fr) 2002-03-05 2004-07-27 Procede pour la preparation de 3-{2-[4-(6-fluorobenzo[d] isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-[1,2-a]pyrimidin-4-one

Country Status (22)

Country Link
US (1) US7205405B2 (fr)
EP (1) EP1480978A1 (fr)
JP (1) JP2005525366A (fr)
KR (1) KR100680003B1 (fr)
CN (1) CN1315826C (fr)
AU (1) AU2003219010A1 (fr)
BR (1) BR0308139A (fr)
CA (1) CA2474811A1 (fr)
CO (1) CO5611140A2 (fr)
CR (1) CR7462A (fr)
ES (1) ES2197801B1 (fr)
IL (1) IL163750A0 (fr)
MA (1) MA26353A1 (fr)
MX (1) MXPA04008289A (fr)
NO (1) NO20043447L (fr)
NZ (1) NZ534463A (fr)
PL (1) PL370502A1 (fr)
RU (1) RU2272037C9 (fr)
TN (1) TNSN04139A1 (fr)
UA (1) UA80114C2 (fr)
WO (1) WO2003074522A1 (fr)
ZA (1) ZA200405939B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100581550C (zh) * 2001-12-05 2010-01-20 杜拉美德药物有限公司 预防怀孕和减少经期前症状的口服避孕药
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
WO2025174820A1 (fr) * 2024-02-12 2025-08-21 Ohio State Innovation Foundation Inhibiteurs d'hétéroaryle topoisomérase et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
CA2000786C (fr) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
ES2074966B1 (es) * 1994-02-11 1996-06-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
DE60009959T2 (de) * 2000-05-05 2005-03-31 Rpg Life Sciences Limited Verfahren zur herstellung von antipsychotischem 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-on

Also Published As

Publication number Publication date
IL163750A0 (en) 2005-12-18
EP1480978A1 (fr) 2004-12-01
CN1639163A (zh) 2005-07-13
CR7462A (es) 2005-02-10
NO20043447L (no) 2004-08-18
JP2005525366A (ja) 2005-08-25
BR0308139A (pt) 2005-01-04
US7205405B2 (en) 2007-04-17
KR100680003B1 (ko) 2007-02-08
ES2197801B1 (es) 2005-03-16
UA80114C2 (en) 2007-08-27
CN1315826C (zh) 2007-05-16
NZ534463A (en) 2006-02-24
TNSN04139A1 (en) 2007-03-12
MXPA04008289A (es) 2004-11-26
CO5611140A2 (es) 2006-02-28
PL370502A1 (en) 2005-05-30
RU2272037C9 (ru) 2006-06-20
US20050143395A1 (en) 2005-06-30
ES2197801A1 (es) 2004-01-01
CA2474811A1 (fr) 2003-09-12
KR20040091679A (ko) 2004-10-28
RU2272037C1 (ru) 2006-03-20
ZA200405939B (en) 2006-06-28
WO2003074522A1 (fr) 2003-09-12
AU2003219010A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
ATE284214T1 (de) Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten
CY2017011I1 (el) 2-(ΠΥΡΙΔΙΝ-2-ΥΛΑΜΙΝΟ)-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΥΝ-7-ΟΝΕΣ
FR2873685B1 (fr) Procede d'obtention de ceramiques poreuses
EP1642136A4 (fr) Procede pour l'isolement d'une proteine
PL1611144T3 (pl) Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
EP1807396A4 (fr) Composes de 2-aminopyridine utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
EP1692150A4 (fr) Procede de preparation de diphosphures de pentaerythrite
MA26353A1 (fr) Procede pour la preparation de 3-{2-[4-(6-fluorobenzo[d] isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-[1,2-a]pyrimidin-4-one
IS4259A (is) Aðferð við að fá fram 3-{2-[4-(6-flúor-bensó[D]isoxasól-3-ýl)píperidín-1-ýl]-etýl}-2-metýl-6,7,8,9-fjórhýdró-4H-pýridó[1,2-A]pýrimidín-4-on
HUP0104873A3 (en) Refined process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
EP1551831A4 (fr) Procede de preparation de la risperidone
EP1646640A4 (fr) Procede pour la preparation de derives de 1-androstene hautement purs
EP1565448A4 (fr) Procede de preparation de 10h-dibenzo b,f 1,4 thiazepin-11-one
IL184781A0 (en) CRYSTALLINE 1H-IMIDAZO[4,5-b]PYRIDIN-5-AMINE, 7-[5-[(CYCLOHEXYLMETHYLAMINO)-METHYL]-1H-INDOL-2-YL]-2-METHYL, SULFATE (1:1), TRIHYDRATE AND ITS PHARMACEUTICAL USES
SI1461338T1 (sl) Izboljšan postopek za pripravo 3-(2-(4-(6-fluoro-1,2-benzizoksazol-3-il)-1-piperidinil)etil)-6,7, 8,9-tetrahidro-2-metil-4H-pirido(1,2-A)pirimidin-4-ona
NO20044629L (no) Fremgangsmate til fremstilling av sure salter av gemifloksasin.
AU2002363610A1 (en) Improved process for the preparation of 3-{2-`4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl!ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido`1,2-a!pyrimidin-4-one
SE0100297D0 (sv) New compounds
SE0100296D0 (sv) New compounds
FR2873686B1 (fr) Procede d'obtention de ceramiques poreuses
HK1066794A (en) Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one
FR2853315B1 (fr) Procede pour la fabrication de derives d'aminoacides
SE0100295D0 (sv) New compounds
NO20033840D0 (no) Fremgangsmåte for fremstilling av mirtazapinmellomprodukter
EP1549623A4 (fr) Procede de preparation de 3-chloromethyl-1,2,4-triazolin-5-one